Clinical trial Recruiting at 1 site Interventional Ages 10 to 13

Promoting health and well-being in African American adolescents

Official title: Can Family-Centered Prevention Programming Reduce Neuroimmune Vulnerabilities for Drug Use and Cardiometabolic Risk Among African American Adolescents? A Randomized Prevention Trial

Run by University of Georgia · NCT05253235 · Data updated 2026-11-12

This study is testing a program designed to help African American kids aged 10-13 and their families build resilience and improve health by strengthening family relationships and coping with stress.

More Substance Use trials

Quick facts

Study typeInterventional
Ages10 Years to 13 Years
SexAll
Enrollment650 (estimated)
SponsorUniversity of Georgia
Academic / other
Locations1 site (Athens, Georgia)
StatusRecruiting
StartedJanuary 25, 2022
Main results expectedDecember 31, 2027
Study endsDecember 31, 2027
Registry record updatedFebruary 23, 2022
Trial IDNCT05253235 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include African American youth aged 10-13 and their primary caregivers who live in the same household.

Probably not a fit

Patients with contraindications for MRI scanning or chronic illnesses that could affect inflammatory measures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Health and Resilience Project (HARP): Foundations aims to evaluate the effectiveness of the Strong African American Families (SAAF) intervention in enhancing the health and resilience of African American adolescents aged 10-13 and their primary caregivers. Participants are randomly assigned to either the SAAF intervention or a control group, with assessments conducted at baseline and follow-up to measure vulnerability to substance use through a neuroimmune model of stress coping. The study seeks to understand how family relationships can mitigate the effects of stress on developing brains and overall health. By focusing on neuroimmune risk markers, the research aims to provide a rigorous evaluation of the SAAF program's impact over two years.

Why it matters

Potential benefit: If successful, this intervention could significantly reduce the risk of substance use and improve overall health outcomes for African American adolescents.

How similar studies have gone: Previous studies have shown promising results with similar interventions aimed at enhancing family dynamics and reducing substance use risk, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Youth:

* Self reported African American or Black;
* Age 10-13

Parents:

* Primary caregiver for youth,
* Resides in same household as youth.

Exclusion Criteria:

Youth :

* Contraindications for MRI scanning (e.g., metal in body, traumatic brain injury, claustrophobia, pregnancy),
* Youth with chronic illnesses or medication regimens that would affect inflammatory panels (e.g., diabetes, congenital heart disease, asthma, cancers).

Parent:

* Conditions (e.g., severe disability, psychoses) that would prevent participation in the SAAF intervention or completing self-report measures.

Where it's running

  • Center for Family Research
    Athens, Georgia, United States
    Recruiting

Study contacts

  • Principal investigator: Gene H Brody, Ph.D. — University of Georgia
  • Study coordinator: Heather Zuercher, MPH
  • Email: zuercher@uga.edu
  • Phone: 706-425-2992

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.